<DOC>
	<DOC>NCT01125657</DOC>
	<brief_summary>This study is to compare its pharmacokinetics profile of two YM150 formulations by 2x2 crossover method.</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B</brief_title>
	<detailed_description />
	<mesh_term>Darexaban</mesh_term>
	<criteria>Body weight: ≥50.0 kg, &lt;80.0 kg BMI: ≥17.6, &lt;26.4 Healthy, as judged by the investigator or subinvestigator based on the results of physical examinations and lab tests Received any investigational drugs within 120 days before the study Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the study Received medication within 7 days before the study A deviation from the assessment criteria of physical examinations or laboratory tests A deviation from the normal reference range of coagulation test [PT (INR) or aPTT] History of drug allergies Upper gastrointestinal disease within 7 days before the study Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases Concurrent or previous malignant tumor Previous treatment with YM150</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>bioequivalence study</keyword>
</DOC>